Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, according to findings from the SURMOUNT-5 trial. As Healio previously reported,

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference. And one clearly comes out on top.

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

As medications become increasingly popular to support weight loss, not all of them are approved by the U.S. Food and Drug Administration. Most prescription weight-loss drugs work by making you feel less hungry or fuller.

In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro and Zepbound) lost more weight and inches from their waist than those who took semaglutide (Ozempic,

Orlistat (sold as Alli) is one effective over-the-counter weight loss aid that is also FDA-approved.

The second episode of Pulse in Focus podcast is here. This time we are giving a guide to tirzepatide prescribing, and an in-depth analysis of ARRS GPs with the Health Foundation.